Organization
Hospital Clinic of Barcelona
2 clinical trials
7 abstracts
Abstract
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.Org: Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Medical Oncology Department, Hospital Universitario 12 De Octubre, Hospital Clinic of Barcelona, Hospital Clinic i Provincial de Barcelona,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).Org: Seoul National University Hospital, Asan Medical Center, University of Ulsan College of Medicine, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,
Abstract
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,
Clinical trial
CHemical OptImization of Cerebral Embolectomy in Patients With Acute Stroke Treated With Mechanical Thrombectomy 2 (CHOICE 2 TRIAL)Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer: a Randomized Prospective Study (PROVIDENCE Trial)Status: Not yet recruiting, Estimated PCD: 2025-02-01
Abstract
Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, SWOG, Hospital Clinic of Barcelona, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma.Org: Newcastle University, Hospital Clinico Universitario de Valencia; INCLIVA; GEICAM Spanish Breast Cancer Group, University of Barcelona, Hospital Clinic of Barcelona, Dermatology Department,
Abstract
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.Org: La Roche-Posay International, Levallois-Perret, Nantes Université, Côte d’Azur University, Nice University Hospital Center,
Abstract
Sun exposure and associated risks: Insight from an international survey with a focus on the population with past medical history of skin cancers.Org: Nantes Université, Côte d’Azur University, Nice University Hospital Center, INSERM U1065, Hospital Clinic of Barcelona,